Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells

Binoj C. Nair, Sreeram Vallabhaneni, Rajeshwar R. Tekmal, Ratna K. Vadlamudi

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Introduction: Current clinical strategies for treating hormonal breast cancer involve the use of anti-estrogens that block estrogen receptor (ER)α functions and aromatase inhibitors that decrease local and systemic estrogen production. Both of these strategies improve outcomes for ERα-positive breast cancer patients, however, development of therapy resistance remains a major clinical problem. Divergent molecular pathways have been described for this resistant phenotype and interestingly, the majority of downstream events in these resistance pathways converge upon the modulation of cell cycle regulatory proteins including aberrant activation of cyclin dependent kinase 2 (CDK2). In this study, we examined whether the CDK inhibitor roscovitine confers a tumor suppressive effect on therapy-resistant breast epithelial cells.Methods: Using various in vitro and in vivo assays, we tested the effect of roscovitine on three hormonal therapy-resistant model cells: (a) MCF-7-TamR (acquired tamoxifen resistance model); (b) MCF-7-LTLTca (acquired letrozole resistance model); and

Original languageEnglish (US)
Article numberR80
JournalBreast Cancer Research
Issue number3
StatePublished - Jun 11 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells'. Together they form a unique fingerprint.

Cite this